Evidence map›Paper›PMID 34815985›Full record

ArticleNeurobiology of stress2021

Multidimensional predictors of antidepressant responses: Integrating mitochondrial, genetic, metabolic and environmental factors with clinical outcomes.

Carla Nasca, Olivia Barnhill, Paolo DeAngelis, Kathleen Watson, Jue Lin, James Beasley, Sarah P Young, Alison Myoraku, Josh Dobbin, Benedetta Bigio and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of stress, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. The researcher's guide to selecting biomarkers in mental health studies.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  3. Review
  4. Article
  5. Review
  6. Towards a multidimensional model of inflamed depression.Brain, behavior, & immunity - health · 2022
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Carla NascaHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, USA.
Olivia BarnhillHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, USA.
Paolo DeAngelisHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, USA.
Kathleen WatsonCenter for Neuroscience in Women's Health, Stanford University, Palo Alto, USA.
Jue LinDepartment of Psychiatry, University of California, San Francisco, San Francisco, USA.
James BeasleyDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Sarah P YoungDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Alison MyorakuCenter for Neuroscience in Women's Health, Stanford University, Palo Alto, USA.
Josh DobbinHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, USA.
Benedetta BigioHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, USA.
Bruce McEwenHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, USA.
Natalie RasgonCenter for Neuroscience in Women's Health, Stanford University, Palo Alto, USA.
Rockefeller University · USStanford University · USDuke University · USNew York University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major depressive disorder (MDD) is a primary psychiatric illness worldwide; there is a dearth of new mechanistic models for the development of better therapeutic strategies. Although we continue to discover individual biological factors, a major challenge is the identification of integrated, multidimensional traits underlying the complex heterogeneity of depression and treatment outcomes. Here, we set out to ascertain the emergence of the novel mitochondrial mediator of epigenetic function acetyl-L-carnitine (LAC) in relation to previously described individual predictors of antidepressant responses to the insulin-sensitizing agent pioglitazone. Herein, we report that i) subjects with MDD and shorter leukocyte telomere length (LTL) show decreased levels of LAC, increased BMI, and a history of specific types of childhood trauma; and that ii) these multidimensional factors spanning mitochondrial metabolism, cellular aging, metabolic function, and childhood trauma provide more detailed signatures to predict longitudinal changes in depression severity in response to pioglitazone than individual factors. The findings of multidimensional signatures involved in the pathophysiology of depression and their role in predicting treatment outcomes provide a starting point for the development of a mechanistic framework linking biological networks and environmental factors to clinical outcomes in pursuit of personalized medicine strategies to effectively treat MDD.

Indexed as

AcetylcarnitineMetabolismStress

Identifiers

PMID34815985
PMCPMC8592929
OpenAlexW3206879592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.